Evidence map›Paper›PMID 37495935›Full record

ArticlePituitary2023

Complications and mortality of Cushing's disease: report on data collected over a 20-year period at a referral centre.

Alessandro Mondin, Filippo Ceccato, Giacomo Voltan, Pierluigi Mazzeo, Renzo Manara, Luca Denaro, Carla Scaroni, Mattia Barbot

Open access · hybridAbstract read
In one paragraph

Article in Pituitary, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 26 citations in OpenAlex.

  1. Addison's disease in Italy: mortality and survival by etiology.Journal of endocrinological investigation · 2026
    Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. European survey on metabolic and cardiovascular risk in Cushing syndrome.Journal of endocrinological investigation · 2025
    Article
  8. Article
  9. Article
  10. Article
  11. Cardiometabolic complications after Cushing's disease remission.Journal of endocrinological investigation · 2025
    Observational
  12. Article
  13. Unusual infections and thrombotic events in Cushing's syndrome.Journal of endocrinological investigation · 2025
    Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Alessandro MondinEndocrinology Unit, Department of Medicine-DIMED, University Hospital of Padova, Via Ospedale Civile, 105, 35128, Padua, Italy.
Filippo CeccatoEndocrinology Unit, Department of Medicine-DIMED, University Hospital of Padova, Via Ospedale Civile, 105, 35128, Padua, Italy.
Giacomo VoltanEndocrinology Unit, Department of Medicine-DIMED, University Hospital of Padova, Via Ospedale Civile, 105, 35128, Padua, Italy.
Pierluigi MazzeoEndocrinology Unit, Department of Medicine-DIMED, University Hospital of Padova, Via Ospedale Civile, 105, 35128, Padua, Italy.
Renzo ManaraNeuroradiology Unit, University Hospital of Padova, Padua, Italy.
Luca DenaroAcademic Neurosurgery, Department of Neurosciences, University of Padova, Padua, Italy.
Carla ScaroniEndocrinology Unit, Department of Medicine-DIMED, University Hospital of Padova, Via Ospedale Civile, 105, 35128, Padua, Italy.
Mattia BarbotEndocrinology Unit, Department of Medicine-DIMED, University Hospital of Padova, Via Ospedale Civile, 105, 35128, Padua, Italy. mattia.barbot@unipd.it.
University of Padua · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

contextCushing's disease (CD) is rare condition burdened by several systemic complications correlated to higher mortality rates. The primary goal of clinicians is to achieve remission, but it is unclear if treatment can also increase life expectancy.

aimTo assess the prevalence of cortisol-related complications and mortality in a large cohort of CD patients attending a single referral centre. MATERIALS AND

methodsThe clinical charts of CD patients attending a referral hospital between 2001 and 2021 were reviewed.

results126 CD patients (median age at diagnosis 39 years) were included. At the last examination, 78/126 (61.9%) of the patients were in remission regardless of previous treatment strategies. Patients in remission showed a significant improvement in all the cardiovascular (CV) comorbidities (p < 0.05). The CV events were more frequent in older patients (p = 0.003), smokers and persistent CD groups (p < 0.05). Most of the thromboembolic (TE) and infective events occurred during active stages of the disease. The CV events were the most frequent cause of death. The standardized mortality ratio (SMR) resulted increased in persistent cases at the last follow-up (SMR 4.99, 95%CI [2.15; 9.83], p < 0.001) whilst it was not higher in those in remission (SMR 1.66, 95%CI [0.34; 4.85], p = 0.543) regardless of the timing or number of treatments carried out. A younger age at diagnosis (p = 0.005), a microadenoma (p = 0.002), and remission status at the last follow-up (p = 0.027) all increased survival. Furthermore, an elevated number of comorbidities, in particular arterial hypertension, increased mortality rates.

conclusionsPatients with active CD presented a poor survival outcome. Remission restored the patients' life expectancy regardless of the timing or the types of treatments used to achieve it. Persistent CD-related comorbidities remained major risk factors.

Indexed as

HypertensionPituitary ACTH HypersecretionAdultAgedComorbidityFollow-Up StudiesHumansReferral and ConsultationTreatment OutcomeCardiovascular complicationsCushingMorbidityMortalitys diseaseSurvival

Identifiers

PMID37495935
PMCPMC10539191
OpenAlexW4385266812

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.